Molecular Imaging Biomarkers for Immune Checkpoint Inhibitor Therapy

Overview

Journal Theranostics

Date 2020 Feb 12

PMID 32042331

Citations 37

Authors

Pim P van de Donk

Laura Kist de Ruijter

Marjolijn N Lub-de Hooge

Adrienne H Brouwers

Anthonie J van der Wekken

Sjoukje F Oosting

Rudolf Sn Fehrmann

Derk Jan A de Groot

Elisabeth Ge de Vries

Affiliations

Soon will be listed here.

Abstract

Immune checkpoint inhibitors (ICIs) have substantially changed the field of oncology over the past few years. ICIs offer an alternative treatment strategy by exploiting the patients' immune system, resulting in a T cell mediated anti-tumor response. These therapies are effective in multiple different tumor types. Unfortunately, a substantial group of patients do not respond to ICIs. Molecular imaging, using single-photon emission computed tomography (SPECT) and positron emission tomography (PET), can provide non-invasive whole-body visualization of tumor and immune cell characteristics and might support patient selection or response evaluations for ICI therapies. In this review, recent studies with F-fluorodeoxyglucose-PET imaging, imaging of immune checkpoints and imaging of immune cells will be discussed. These studies are until now mainly exploratory, but the first results suggest that molecular imaging biomarkers could have a role in the evaluation of ICI therapy.

Citing Articles

Advancing precision cancer immunotherapy drug development, administration, and response prediction with AI-enabled Raman spectroscopy.

Chadokiya J, Chang K, Sharma S, Hu J, Lill J, Dionne J Front Immunol. 2025; 15():1520860.

PMID: 39850874 PMC: 11753970. DOI: 10.3389/fimmu.2024.1520860.

Zirconium 89 and Copper 64 for ImmunoPET: From Antibody Bioconjugation and Radiolabeling to Molecular Imaging.

Badier L, Quelven I Pharmaceutics. 2024; 16(7).

PMID: 39065579 PMC: 11279968. DOI: 10.3390/pharmaceutics16070882.

Peptide-based PET tracer targeting LAG-3 for evaluating the efficacy of immunotherapy in melanoma.

Yuan P, Long Y, Wei N, Wang Y, Zhu Z, Han J J Immunother Cancer. 2024; 12(7).

PMID: 39043603 PMC: 11284866. DOI: 10.1136/jitc-2024-009010.

Prognostic value of systemic immune-inflammation index/albumin ratio for immunotherapy-treated patients receiving opioids.

Yan L, Kang P, Cao C, Jinhui B, Yong L PLoS One. 2024; 19(6):e0305119.

PMID: 38935663 PMC: 11210763. DOI: 10.1371/journal.pone.0305119.

The development process of 'fit-for-purpose' imaging biomarkers to characterize the tumor microenvironment.

Eertink J, Bahce I, Waterton J, Huisman M, Boellaard R, Wunder A Front Med (Lausanne). 2024; 11:1347267.

PMID: 38818386 PMC: 11138661. DOI: 10.3389/fmed.2024.1347267.

References

Pitt J, Marabelle A, Eggermont A, Soria J, Kroemer G, Zitvogel L . Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016; 27(8):1482-92. DOI: 10.1093/annonc/mdw168. View

Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N . Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. PMC: 5705936. DOI: 10.1056/NEJMoa1507643. View

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

Jagoda E, Vasalatiy O, Basuli F, Opina A, Williams M, Wong K . Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab. Mol Imaging. 2019; 18:1536012119829986. PMC: 6498777. DOI: 10.1177/1536012119829986. View

Vilain R, Menzies A, Wilmott J, Kakavand H, Madore J, Guminski A . Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma. Clin Cancer Res. 2017; 23(17):5024-5033. DOI: 10.1158/1078-0432.CCR-16-0698. View

Mansfield A, Aubry M, Moser J, Harrington S, Dronca R, Park S . Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Ann Oncol. 2016; 27(10):1953-8. PMC: 5035793. DOI: 10.1093/annonc/mdw289. View

Russ B, Prier J, Rao S, Turner S . T cell immunity as a tool for studying epigenetic regulation of cellular differentiation. Front Genet. 2013; 4:218. PMC: 3824109. DOI: 10.3389/fgene.2013.00218. View

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Ehlerding E, Lee H, Jiang D, Ferreira C, Zahm C, Huang P . Antibody and fragment-based PET imaging of CTLA-4+ T-cells in humanized mouse models. Am J Cancer Res. 2019; 9(1):53-63. PMC: 6356917. View

10.

Ferris R, Blumenschein Jr G, Fayette J, Guigay J, Colevas A, Licitra L . Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19):1856-1867. PMC: 5564292. DOI: 10.1056/NEJMoa1602252. View

11.

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

12.

Champiat S, Ferrara R, Massard C, Besse B, Marabelle A, Soria J . Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat Rev Clin Oncol. 2018; 15(12):748-762. DOI: 10.1038/s41571-018-0111-2. View

13.

Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma A . Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 2000; 35(13):1773-82. DOI: 10.1016/s0959-8049(99)00229-4. View

14.

Madore J, Vilain R, Menzies A, Kakavand H, Wilmott J, Hyman J . PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res. 2014; 28(3):245-53. DOI: 10.1111/pcmr.12340. View

15.

Tavare R, Escuin-Ordinas H, Mok S, McCracken M, Zettlitz K, Salazar F . An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy. Cancer Res. 2015; 76(1):73-82. PMC: 4703530. DOI: 10.1158/0008-5472.CAN-15-1707. View

16.

Lo Russo G, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G . Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. Clin Cancer Res. 2018; 25(3):989-999. DOI: 10.1158/1078-0432.CCR-18-1390. View

17.

Rashidian M, Ingram J, Dougan M, Dongre A, Whang K, LeGall C . Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells. J Exp Med. 2017; 214(8):2243-2255. PMC: 5551571. DOI: 10.1084/jem.20161950. View

18.

Jiemy W, Heeringa P, Kamps J, van der Laken C, Slart R, Brouwer E . Positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging of macrophages in large vessel vasculitis: Current status and future prospects. Autoimmun Rev. 2018; 17(7):715-726. DOI: 10.1016/j.autrev.2018.02.006. View

19.

den Hollander M, Bensch F, Glaudemans A, Oude Munnink T, Enting R, den Dunnen W . TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET. J Nucl Med. 2015; 56(9):1310-4. DOI: 10.2967/jnumed.115.154401. View

20.

Li D, Cheng S, Zou S, Zhu D, Zhu T, Wang P . Immuno-PET Imaging of Zr Labeled Anti-PD-L1 Domain Antibody. Mol Pharm. 2018; 15(4):1674-1681. DOI: 10.1021/acs.molpharmaceut.8b00062. View